2810422O20Rik Inhibitors

Mettl18 Inhibitors constitute a group of compounds that indirectly impede the function of the methyltransferase like 18 enzyme by altering the cellular availability of substrates or by modifying the epigenetic environment in which METTL18 operates. Adenosine periodate and sinefungin directly target the universal methyl donor S-adenosylmethionine, reducing its availability for use by METTL18. Methylthioadenosine, a byproduct of polyamine biosynthesis, similarly competes with the methyl donor substrate, potentially diminishing the effective enzymatic activity of METTL18.

Decitabine and 5-azacytidine, both nucleoside analogs, are incorporated into nucleic acids, thereby influencing the overall methylation status within the cell, which can create a ripple effect that alters the functionality of various methyltransferases, including METTL18. Other compounds such as RG108, hydralazine, and procainamide are known to target DNA methyltransferases, which can indirectly affect the transcriptional regulation of genes that may interact with or modify METTL18 activity. Quercetin, by inhibiting multiple kinases, can affect cellular signaling pathways, potentially influencing METTL18's role in these pathways. Disulfiram, a compound with a broad range of enzyme-inhibiting capabilities, could impede the action of METTL18 by affecting its catalytic activity. BIX-01294 and chaetocin, while primarily known for their inhibitory effects on other methyltransferases such as G9a and histone methyltransferases, respectively, might also have off-target effects that could extend to modulating METTL18 activity.